CN Patent

CN104055730A — 马来酸依那普利口服溶液及其制备方法

Assigned to BEIJING D-VENTUREPHARM TECHNOLOGY DEVELOPMENT Co Ltd · Expires 2014-09-24 · 12y expired

What this patent protects

本发明包含一种用于口服给药的稳定的依那普利粉末组合物。具体涉及一种稳定的依那普利口服的液体组合物。本发明所述的依那普利组合物可用于治疗高血压，心脏衰竭以及心室功能障碍等。该组合物优于依那普利，能更好地被人体吸收，口感良好，适用于儿童老年人服用，显著增加患者的服药依从性。

USPTO Abstract

本发明包含一种用于口服给药的稳定的依那普利粉末组合物。具体涉及一种稳定的依那普利口服的液体组合物。本发明所述的依那普利组合物可用于治疗高血压，心脏衰竭以及心室功能障碍等。该组合物优于依那普利，能更好地被人体吸收，口感良好，适用于儿童老年人服用，显著增加患者的服药依从性。

Drugs covered by this patent

Patent Metadata

Patent number
CN104055730A
Jurisdiction
CN
Classification
—
Expires
2014-09-24
Drug substance claim
No
Drug product claim
No
Assignee
BEIJING D-VENTUREPHARM TECHNOLOGY DEVELOPMENT Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.